Bridgeway Capital Management’s Actinium Pharmaceuticals ATNM Stock Holding History

Bridgeway Capital Management’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$39.8K	Hold	40,000	–	–	﹤0.01%	1196
2025 Q4	$54.4K	Hold	40,000	–	–	﹤0.01%	1180
2025 Q3	$64K	Hold	40,000	–	–	﹤0.01%	1150
2025 Q2	$56K	Sell	40,000 -35,000	-47%	-$52.4K	﹤0.01%	1130
2025 Q1	$121K	Sell	75,000 -700	-0.9%	-$889	﹤0.01%	1005
2024 Q4	$95.4K	Sell	75,700 -1,300	-2%	-$2.02K	﹤0.01%	1116
2024 Q3	$145K	Sell	77,000 -6,966	-8%	-$27.5K	﹤0.01%	1116
2024 Q2	$621K	Hold	83,966	–	–	0.01%	812
2024 Q1	$657K	Hold	83,966	–	–	0.01%	847
2023 Q4	$427K	Buy	83,966 +20,000	+31%	+$103K	0.01%	977
2023 Q3	$379K	Hold	63,966	–	–	0.01%	958
2023 Q2	$475K	Hold	63,966	–	–	0.01%	916
2023 Q1	$604K	Sell	63,966 -25,000	-28%	-$264K	0.02%	840
2022 Q4	$947K	Hold	88,966	–	–	0.02%	742
2022 Q3	$657K	Hold	88,966	–	–	0.02%	827
2022 Q2	$428K	Hold	88,966	–	–	0.01%	917
2022 Q1	$455K	Hold	88,966	–	–	0.01%	958
2021 Q4	$535K	Buy	88,966 +9,800	+12%	+$73.5K	0.01%	964
2021 Q3	$701K	Sell	79,166 -20,000	-20%	-$139K	0.01%	934
2021 Q2	$784K	Buy	99,166 +14,767	+17%	+$116K	0.01%	938
2021 Q1	$643K	Buy	84,399 +15,500	+22%	+$132K	0.01%	1026
2020 Q4	$537K	Buy	68,899 +2,000	+3%	+$21.7K	0.01%	928
2020 Q3	$648K	Buy	66,899 +57,732	+630%	+$637K	0.01%	805
2020 Q2	$97K	Buy	+9,167	New	+$69.4K	﹤0.01%	1233
2019 Q3	–	Sell	-1,070	Closed	-$8K	–	1314
2019 Q2	$8K	Hold	1,070	–	–	﹤0.01%	1301
2019 Q1	$15K	Hold	1,070	–	–	﹤0.01%	1332
2018 Q4	$12K	Sell	1,070 -4,673	-81%	-$79.7K	﹤0.01%	1359
2018 Q3	$128K	Hold	5,743	–	–	﹤0.01%	1367
2018 Q2	$110K	Hold	5,743	–	–	﹤0.01%	1357
2018 Q1	$63K	Hold	5,743	–	–	﹤0.01%	1347
2017 Q4	$114K	Hold	5,743	–	–	﹤0.01%	1320
2017 Q3	$99K	Sell	5,743 -5,000	-47%	-$110K	﹤0.01%	1343
2017 Q2	$393K	Buy	10,743 +2,736	+34%	+$114K	﹤0.01%	1151
2017 Q1	$363K	Hold	8,007	–	–	﹤0.01%	1156
2016 Q4	$210K	Hold	8,007	–	–	﹤0.01%	1303
2016 Q3	$324K	Hold	8,007	–	–	﹤0.01%	1223
2016 Q2	$425K	Hold	8,007	–	–	0.01%	1112
2016 Q1	$478K	Buy	8,007 +2,667	+50%	+$168K	0.01%	1076
2015 Q4	$517K	Hold	5,340	–	–	0.01%	1047
2015 Q3	$284K	Buy	5,340 +1,539	+40%	+$103K	0.01%	1231
2015 Q2	$302K	Buy	+3,801	New	+$324K	0.01%	1248
2015 Q1	–	Sell	-1,705	Closed	-$301K	–	1479
2014 Q4	$301K	Sell	1,705 -225	-12%	-$42.7K	0.01%	1222
2014 Q3	$388K	Buy	1,930 +987	+105%	+$196K	0.01%	1195
2014 Q2	$204K	Buy	+943	New	+$314K	0.01%	1328

Other funds holding ATNM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bridgeway Capital Management's ATNM Position: Q1 2026 in Review

Bridgeway Capital Management held its Actinium Pharmaceuticals (ATNM) position steady in Q1 2026 at 40,000 shares worth $39.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1196.

Bridgeway Capital Management first reported a position in ATNM in Q2 2014 and has held it in 44 quarters since. The position peaked at $947K in Q4 2022. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.

Bridgeway Capital Management held 40,000 shares of Actinium Pharmaceuticals worth $39.8K as of Q1 2026.
Bridgeway Capital Management left its Actinium Pharmaceuticals share count unchanged in Q1 2026.
Actinium Pharmaceuticals made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #1196 holding.
Bridgeway Capital Management first reported a position in Actinium Pharmaceuticals in Q2 2014 and has held it in 44 quarters since.
Bridgeway Capital Management's Actinium Pharmaceuticals position peaked at $947K in Q4 2022.
54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.